Clinical, pathological and genomic features of infratentorial IDH-mutant gliomas

被引：0
|
作者：
Wang, L. [1 ]
机构：
[1] Xuanwu Hosp, Pathol, Beijing, Peoples R China
来源：
BRAIN PATHOLOGY | 2023年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
eP-NO-A74
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Clinical applications and prospects of PET imaging in patients with IDH-mutant gliomas
    Michael M. Wollring
    Jan-Michael Werner
    Garry Ceccon
    Philipp Lohmann
    Christian P. Filss
    Gereon R. Fink
    Karl-Josef Langen
    Norbert Galldiks
    Journal of Neuro-Oncology, 2023, 162 : 481 - 488
  • [22] IDH-mutant gliomas in children and adolescents - from biology to clinical trials
    Evans, Louise
    Trinder, Sarah
    Dodgshun, Andrew
    Eisenstat, David D.
    Whittle, James R.
    Hansford, Jordan R.
    Valvi, Santosh
    FRONTIERS IN ONCOLOGY, 2025, 14
  • [23] CHARACTERISTICS OF IDH-MUTANT GLIOMAS WITH NON-CANONICAL IDH MUTATIONS
    Poetsch, L.
    Dehais, C.
    Frenel, J.
    Siegfried, A.
    Lacomme, S.
    Seizeur, R.
    Larrieu-Ciron, D.
    Cappellen, D.
    Loussouarn, D.
    Ferec, C.
    Eimer, S.
    Carpentier, C.
    Sanson, M.
    Delattre, J.
    Figarella-Branger, D.
    Ducray, F.
    NEURO-ONCOLOGY, 2019, 21 : 31 - 31
  • [24] Characteristics of IDH-mutant gliomas with non-canonical IDH mutation
    L. Poetsch
    C. Bronnimann
    H. Loiseau
    J. S. Frénel
    A. Siegfried
    R. Seizeur
    G. Gauchotte
    D. Cappellen
    C. Carpentier
    D. Figarella-Branger
    S. Eimer
    D. Meyronet
    F. Ducray
    Journal of Neuro-Oncology, 2021, 151 : 279 - 286
  • [25] Characteristics of IDH-mutant gliomas with non-canonical IDH mutation
    Poetsch, L.
    Bronnimann, C.
    Loiseau, H.
    Frenel, J. S.
    Siegfried, A.
    Seizeur, R.
    Gauchotte, G.
    Cappellen, D.
    Carpentier, C.
    Figarella-Branger, D.
    Eimer, S.
    Meyronet, D.
    Ducray, F.
    JOURNAL OF NEURO-ONCOLOGY, 2021, 151 (02) : 279 - 286
  • [26] Epigenetic Reprogramming for Targeting IDH-Mutant Malignant Gliomas
    Park, Jong-Whi
    Turcan, Sevin
    CANCERS, 2019, 11 (10)
  • [27] From Laboratory Studies to Clinical Trials: Temozolomide Use in IDH-Mutant Gliomas
    Sun, Xueyuan
    Turcan, Sevin
    CELLS, 2021, 10 (05)
  • [28] THE PROGNOSTIC IMPLICATION OF MGMT PROMOTER METHYLATION IN IDH-MUTANT GLIOMAS
    Youssef, Gilbert
    Aquilanti, Elisa
    Muzikansky, Alona
    Miller, Julie
    Vogelzang, Jayne
    Lapinskas, Emily
    Lim-Fat, Mary Jane
    Rahman, Rifaquat
    Beroukhim, Rameen
    Bi, Wenya Linda
    Chukwueke, Ugonma
    Castro, Luis Nicolas Gonzalez
    Lee, Eudocia
    McFaline-Figueroa, J. Ricardo
    Nayak, Lakshmi
    Reardon, David A.
    Ligon, Keith
    Wen, Patrick Y.
    NEURO-ONCOLOGY, 2022, 24 : 153 - 153
  • [29] Exploiting nanopore sequencing for characterization and grading of IDH-mutant gliomas
    Wongsurawat, Thidathip
    Jenjaroenpun, Piroon
    Anekwiang, Panatna
    Arigul, Tantip
    Thongrattana, Wichayapat
    Jamshidi-Parsian, Azemat
    Boysen, Gunnar
    Suriyaphol, Prapat
    Suktitipat, Bhoom
    Srirabheebhat, Prajak
    Cheunsuchon, Pornsuk
    Tanboon, Jantima
    Nookaew, Intawat
    Sathornsumetee, Sith
    BRAIN PATHOLOGY, 2024, 34 (01)
  • [30] NON-INVASIVE DIAGNOSIS OF IDH-MUTANT BRAINSTEM GLIOMAS
    Kushnirsky, Marina
    Thakur, Sunitha
    Karajannis, Matthias
    Bale, Tejus
    Rosenblum, Marc
    Malani, Rachna
    Gavrilovic, Igor T.
    Schaff, Lauren
    Pentsova, Elena
    Grommes, Christian
    Moss, Nelson
    Sait, Sameer Farouk
    Hill, Katherine
    Miller, Alexandra
    Mellinghoff, Ingo
    Young, Robert
    Lin, Andrew
    NEURO-ONCOLOGY, 2022, 24 : 176 - 177
12345